Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

412 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.
Berg SL, Blaney SM, Devidas M, Lampkin TA, Murgo A, Bernstein M, Billett A, Kurtzberg J, Reaman G, Gaynon P, Whitlock J, Krailo M, Harris MB; Children's Oncology Group. Berg SL, et al. Among authors: kurtzberg j. J Clin Oncol. 2005 May 20;23(15):3376-82. doi: 10.1200/JCO.2005.03.426. J Clin Oncol. 2005. PMID: 15908649 Clinical Trial.
Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group.
Tower RL, Jones TL, Camitta BM, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, Kurtzberg J. Tower RL, et al. Among authors: kurtzberg j. J Pediatr Hematol Oncol. 2014 Jul;36(5):353-61. doi: 10.1097/MPH.0000000000000131. J Pediatr Hematol Oncol. 2014. PMID: 24608079 Free PMC article. Clinical Trial.
Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, Camitta BM, Kurtzberg J; Children's Oncology Group. Salzer WL, et al. Among authors: kurtzberg j. J Pediatr Hematol Oncol. 2007 Jun;29(6):369-75. doi: 10.1097/MPH.0b013e3180640d54. J Pediatr Hematol Oncol. 2007. PMID: 17551397 Clinical Trial.
Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, Camitta BM. Kurtzberg J, et al. J Pediatr Hematol Oncol. 2011 Dec;33(8):610-6. doi: 10.1097/MPH.0b013e31822d4d4e. J Pediatr Hematol Oncol. 2011. PMID: 22042277 Free PMC article. Clinical Trial.
Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.
Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, Camitta B. Chauvenet AR, et al. Among authors: kurtzberg j. Blood. 2007 Aug 15;110(4):1105-11. doi: 10.1182/blood-2006-12-061689. Epub 2007 Apr 18. Blood. 2007. PMID: 17442849 Free PMC article. Clinical Trial.
Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study.
Wacker P, Land VJ, Camitta BM, Kurtzberg J, Pullen J, Harris MB, Shuster JJ; Children's Oncology Study Group. Wacker P, et al. Among authors: kurtzberg j. J Pediatr Hematol Oncol. 2007 Sep;29(9):627-32. doi: 10.1097/MPH.0b013e3181483df1. J Pediatr Hematol Oncol. 2007. PMID: 17805038 Clinical Trial.
412 results